WO2018084474A1

WO2018084474A1 - Nanoparticle focusing device and driving method therefor

Info

Publication number: WO2018084474A1
Application number: PCT/KR2017/011647
Authority: WO
Inventors: 이용흠
Original assignee: 연세대학교 원주산학협력단
Priority date: 2016-11-03
Filing date: 2017-10-20
Publication date: 2018-05-11
Also published as: KR20180049580A; KR101916413B1

Abstract

The present invention relates to a nanoparticle focusing device, and the nanoparticle focusing device comprises: at least one magnetic field generating unit for generating a magnetic field; at least one magnetic body magnetized by the magnetic field; and a control unit for generating a control signal for controlling the operation of the magnetic field generating unit, wherein the magnetic body is magnetized by the magnetic field such that a nanoparticle containing a drug introduced into a living body can be focused at an affected part within a region of the magnetic field.

Description

Nanoparticle Concentrator and its Driving Method

The present application relates to a nanoparticle concentrator and a driving method thereof.

In the treatment of cancer, the user's body should be administered with substantially more amount of anticancer agent than the amount of anticancer agent that is needed where the cancer occurred due to the human blood circulation. If the anticancer drug is administered to the human body more than necessary, it adversely affects other tissues and organs, causing a number of side effects, such as nausea, vomiting, hair loss, infection, fatigue, anemia, bleeding, diarrhea, skin and nails. There is discoloration, a heat phenomenon.

To overcome this problem, research and development on drug delivery systems (DDS) to increase the targeting efficiency of anticancer drugs are actively conducted in order to prevent the administration of anticancer drugs more than necessary.

A drug delivery system is a system that improves administration techniques and formulations and controls the in vivo transport of drugs to increase the stability, effectiveness or reliability of the drug to the living body, which selectively delivers the minimum amount of drug required to the site of action. It is also desired to administer so that the desired concentration is maintained.

One of the various methods of implementing a drug delivery system is the use of nanoparticles, which injects drugs into nanoparticles attracted to a magnet, and induces a substance to a desired lesion using a single magnet. to be.

However, the ratio of inducing a substance to a desired position in the human body is extremely low, which lowers the targeting efficiency of the drug. In addition, the conventional method is only capable of inducing the substance only in the affected part of the skin surface, there is a problem that does not induce the substance to the organs existing in the deep (deep) in the human body. Therefore, it is effective in the treatment of diseases such as skin cancer present on the skin surface, but the effect is less effective in the treatment of diseases occurring in the deep inside of the human body.

The background technology of the present application is disclosed in Korean Patent Publication No. 10-1406632 (Registration Date: 2014.06.03).

The present invention is to solve the above-mentioned problems of the prior art, to provide a nanoparticle concentrating device and a driving method thereof that can significantly increase the rate of drug induction by concentrating the nanoparticles in the affected area to maximize the drug treatment effect For the purpose of

The present application is to solve the above-mentioned problems of the prior art, and to provide a nanoparticle concentrating device and a driving method thereof capable of conducting heat to the nanoparticles concentrated on the affected area to suppress the proliferation of cancer cells and necrosis the cancer cells. do.

However, the technical problem to be achieved by the embodiments of the present application is not limited to the technical problems as described above, and other technical problems may exist.

As a technical means for achieving the above technical problem, the nanoparticle concentrator according to an embodiment of the present application, at least one magnetic field generating unit for generating a magnetic field, at least one magnetic material magnetized by the magnetic field and the magnetic field generation And a control unit configured to generate a control signal for controlling a negative operation, wherein the magnetic body may concentrate nanoparticles including a drug introduced into a living body as magnetized by the magnetic field to affected areas in the region of the magnetic field. have.

The controller may control at least one of the strength, frequency, time, and pattern of the magnetic field as a type of the magnetic field generated from the magnetic field generator.

In addition, the controller may control the type of the magnetic field to concentrate the nanoparticles or conduct heat to the nanoparticles.

The control unit controls the frequency of the magnetic field to any one of 100 kHz to 300 kHz, and the magnetic material is magnetized or demagnetized by a magnetic field having any one of the frequencies of 100 kHz to 300 kHz to generate heat. It can conduct heat to nanoparticles.

In addition, the nanoparticle concentrator according to an embodiment of the present application further comprises a sensor unit for measuring the number of nanoparticles concentrated on the affected part, the control unit, whether the number of nanoparticles concentrated on the affected part exceeds a predetermined criterion Depending on whether or not the type of the magnetic field can be changed from the first type to the second type.

The control unit may control the type of the magnetic field to a frequency of 30 Hz or less as a first type to concentrate the nanoparticles, and when it is determined that the number of nanoparticles concentrated on the affected part exceeds a predetermined criterion. The type of the magnetic field is controlled as a second type at a frequency between 100 kHz and 300 kHz, and the magnetic material is magnetized or demagnetized by a magnetic field having the frequency of the second type to generate heat to heat the nanoparticles. I can evangelize.

The control unit may control the type of the magnetic field to a frequency of 30 Hz or less as a first type for a preset first time to concentrate the nanoparticles, and set a second preset time after the first time has elapsed. While the type of the magnetic field is controlled to a frequency between 100 kHz and 300 kHz as a second type, and the magnetic material is magnetized or demagnetized by a magnetic field having a frequency of the second type to generate heat to the nanoparticles. Can evangelize.

In addition, the magnetic body may be located in the affected part by being located in the magnetic field generating part or by at least one of attachment, insertion, and implantation.

In addition, the magnetic body located in the magnetic field generating unit may include a magnetic needle and a spherical magnetic body coupled to the end of the magnetic needle.

The magnetic field generating unit may include a magnetic field core having a through hole and a coil wound around the magnetic field core, and the magnetic material may be positioned through the through hole.

In addition, the magnetic body may be a spherical magnetic body.

The controller may change the frequency of the magnetic field at predetermined time intervals.

In addition, when the plurality of magnetic field generators are included, the controller may control different types of magnetic fields generated from each of the plurality of magnetic field generators.

The magnetic field generating unit may generate a pulsed electro-magnetic field (PEMF).

The magnetic field generating unit may include a first magnetic field generating unit, a second magnetic field generating unit, and a third magnetic field generating unit, and the first magnetic field generating unit, the second magnetic field generating unit, and the third magnetic field generating unit respectively generate a magnetic field. It can be arranged at a triangular angle so that the regions of cross each other.

On the other hand, the driving method of the nanoparticle concentrator according to an embodiment of the present invention includes generating a magnetic field control signal, generating a magnetic field based on the magnetic field control signal and magnetizing the magnetic body by the magnetic field can do.

The generating of the magnetic field control signal may include: (a) generating a control signal for controlling the type of the magnetic field at a frequency of 30 Hz or less as a first type, and (b) the magnetic field after the step (a). Generating a control signal for controlling the type of to be a frequency between 100 kHz and 300 kHz as a second type, wherein the method for driving the nanoparticle concentrator is provided from a magnetic material magnetized by the magnetic field of the second type. The method may further include generating heat.

The above-mentioned means for solving the problems are merely exemplary and should not be construed as limiting the present application. In addition to the above-described exemplary embodiments, additional embodiments may exist in the drawings and detailed description of the invention.

According to the aforementioned problem solving means of the present application, as the magnetic material is magnetized by the magnetic field, by concentrating the nanoparticles containing the drug introduced into the living body in the affected area in the magnetic field region, the rate at which the drug is induced (targeting ratio) is significantly increased. It is effective to maximize the drug treatment effect.

According to the above-described problem solving means of the present invention, by concentrating the nanoparticles to the affected area, by controlling the type of magnetic field differently to conduct heat to the concentrated nanoparticles there is an effect that can inhibit the proliferation of cancer cells and necrosis cancer cells.

In addition, the effects obtainable herein are not limited to the effects mentioned above, and other effects not mentioned may be clearly understood by those skilled in the art from the following description. will be.

1 is a schematic block diagram of a nanoparticle concentrator according to an embodiment of the present disclosure.

FIG. 2A is a view schematically illustrating a configuration of a magnetic field generator according to a first embodiment in a nanoparticle concentrator according to an embodiment of the present disclosure.

Figure 2b is a view showing the configuration of a magnetic body in the nanoparticle concentrator according to an embodiment of the present application.

3 is a view schematically showing the configuration of the magnetic field generating unit according to the second embodiment in the nanoparticle concentrator according to the embodiment of the present application.

4 is a view showing an example of the magnetic field stimulation mode method in the nanoparticle concentrator according to an embodiment of the present application.

5 is a view showing a concentrated mode and a heating mode in the nanoparticle concentrator according to an embodiment of the present application.

6 is a view showing the configuration of a plurality of magnetic field generating unit in the nanoparticle concentrator according to an embodiment of the present application.

7 is a view showing another configuration of the plurality of magnetic field generating unit in the nanoparticle concentrator according to an embodiment of the present application.

8 is a schematic operation flowchart of a method of driving a nanoparticle concentrator according to an embodiment of the present application.

DETAILED DESCRIPTION Hereinafter, exemplary embodiments of the present disclosure will be described in detail with reference to the accompanying drawings so that those skilled in the art may easily implement the present disclosure. As those skilled in the art would realize, the described embodiments may be modified in various different ways, all without departing from the spirit or scope of the present invention. In the drawings, parts irrelevant to the description are omitted for simplicity of explanation, and like reference numerals designate like parts throughout the specification.

Throughout this specification, when a part is "connected" to another part, it is not only "directly connected" but also "electrically connected" or "indirectly connected" with another element in between. "Includes the case.

Throughout this specification, when a member is said to be located on another member "on", "upper", "top", "bottom", "bottom", "bottom", this means that any member This includes not only the contact but also the presence of another member between the two members.

Throughout this specification, when a part is said to "include" a certain component, it means that it can further include other components, without excluding the other components unless specifically stated otherwise.

The present application focuses nanoparticles including drugs introduced into a living body to the affected area, and controls the type of magnetic field to differently control the type of magnetic field to conduct heat to the concentrated nanoparticles, thereby inhibiting the proliferation of cancer cells and necrotic cancer cells. And a driving method thereof.

Referring to FIG. 1, the nanoparticle concentrator 100 according to an exemplary embodiment of the present disclosure may include a magnetic field generator 110, a magnetic body 120, and a controller 130.

The magnetic field generator 110 may generate a magnetic field based on a control signal from the controller 130, and the nanoparticle concentrator 100 may include at least one magnetic field generator 110. In this case, the magnetic field generated from the magnetic field generating unit 110 may be a pulsed electro-magnetic field (PEMF).

The magnetic body 120 may be magnetized by a magnetic field generated from the magnetic field generator 110, and the nanoparticle concentrator 100 may include at least one magnetic body 120.

In addition, as the magnetic body 120 is magnetically generated by the magnetic field generated from the magnetic field generator 110, the nanoparticles containing the drug introduced into the user's body (or living body) 1 concentrate on the affected part in the magnetic field s region. You can. A more detailed description is as follows.

According to the first embodiment, the magnetic field generating unit 110 and the magnetic body 120 may be formed in the shape as shown in FIGS. 2A and 2B according to the first embodiment, or may be formed in the shape as shown in FIG. 3 according to the second embodiment. have.

First, the shapes of the magnetic field generating unit 110 ′ and the magnetic body 120 ′ according to the first embodiment may be more easily understood with reference to FIGS. 2A and 2B.

2A is a view schematically showing the configuration of the magnetic field generating unit 110 ′ according to the first embodiment in the nanoparticle concentrator 100 according to an embodiment of the present disclosure, and FIG. In the nanoparticle concentrator 100, the magnetic body 120 ′ according to the first embodiment is illustrated.

2A and 2B, in the nanoparticle concentrator 100 according to an embodiment of the present disclosure, the magnetic field generating unit 110 ′ according to the first embodiment may include a magnetic field core having a through hole 110a formed at a central portion thereof. 110b) and a coil 110c wound around the magnetic field core 110b. The magnetic field core 110b may be, for example, a cylindrical shape, but is not limited thereto. In addition, the coil 110c may be provided in a form wound on the magnetic field core 110b.

In addition, in the nanoparticle concentrator 100 according to the exemplary embodiment of the present disclosure, the magnetic body 120 ′ according to the first embodiment is a magnetic needle 120a and a spherical magnetic body 120b coupled to one end of the magnetic needle 120a. It may include. Here, the spherical magnetic body 120b may be formed with a diameter larger than the diameter of the magnetic needle 120a so that the nanoparticles can be concentrated in the magnetic field region as much as possible, and the term 'diameter' refers to a diameter of a circular shape. Rather than narrowly interpreted, it can be interpreted broadly to mean various widths (widths). In addition, the magnetic body 120 ′ according to the first embodiment of the present disclosure is illustrated as having a spherical magnetic body 120b formed in a spherical shape, but is not limited thereto. The shape may be variously modified.

In addition, the magnetic body 120 ′ according to the first embodiment may be located in the through hole 110 a of the magnetic field generating unit 110 ′, and a portion of the magnetic needle 120 a passes through the through hole 110 a. can do. In addition, the magnetic needle 120a may serve as an injection needle. Accordingly, the spherical magnetic body 120b formed at the end of the magnetic body 120 ′ and a portion of the magnetic body needle 120a may be part of the user's body 1. ) May be inserted as an injection needle.

2A illustrates an example in which a part of the magnetic body 120 ′ is inserted into the body 1 of the user. When the magnetic field is generated through the magnetic field generating unit 110 ′ in this state, The magnetic field region s may be formed in the peripheral region around the spherical magnetic body 120b formed at the end of the magnetic body 120 '. In addition, since the magnetic body 120 'is magnetized by the magnetic field generated from the magnetic field generating unit 110', the nanoparticles 2 including the drug introduced into the living body 1 are affected by the affected area, particularly in the magnetic field region s. It can be concentrated in cancerous tissues.

Meanwhile, the shapes of the magnetic field generating unit 110 ″ and the magnetic body 120 ″ according to the second embodiment may be more easily understood with reference to FIG. 3.

Referring to FIG. 3, in the nanoparticle concentrator 100 according to an embodiment of the present disclosure, the magnetic field generator 110 ″ according to the second embodiment may be formed in the magnetic field core 110b ′ and the magnetic field core 110b ′. It may include a wound coil (110c '). Here, the magnetic field core 110b 'of the magnetic field generating unit 110' 'according to the second embodiment has a through-hole in the center of the magnetic field core 110b of the magnetic field generating unit 110' according to the first embodiment. It may be missing. The magnetic field core 110b 'may be, for example, a cylindrical shape, but is not limited thereto. In addition, the coil 110c 'may be provided in a form wound on the magnetic field core 110b'.

In addition, in the nanoparticle concentrator 100 according to an embodiment of the present disclosure, the magnetic body 120 ″ according to the second embodiment may be a spherical magnetic body. The magnetic body 120 ″ according to the second embodiment may be located at the affected part of the user's body 1 by at least one of attachment, insertion, and implantation. That is, the magnetic body 120 ″ may be attached to the surface of the user's body 1 or may be inserted or implanted in the user's body 1. Although the shape of the magnetic body 120 ″ is illustrated as being spherical, the shape of the magnetic body 120 ″ is not limited thereto.

3 illustrates a case where the magnetic body 120 ″ is attached to the surface of the user's body 1 as an example, and generates a magnetic field through the magnetic field generating unit 110 ″ in this state. In this case, a magnetic field region s dl may be formed in the peripheral region around the magnetic body 120 ″. In addition, the magnetic body 120 '' is magnetized by the magnetic field generated from the magnetic field generating unit 110 '' so that the nanoparticles 2 including the drug introduced into the living body 1 may be affected by the affected part in the magnetic field region s. , Especially in cancerous tissues.

The controller 130 may generate a control signal for controlling the operation of the magnetic field generator 120. The controller 130 may generate a control signal based on the user input.

When the magnetic field is generated from the magnetic field generator 110 based on the control signal of the controller 130, the magnetic body 120 is nano-containing a drug introduced into the user's body (or living body, 1) as it is magnetized by the magnetic field Particles 2 can be concentrated in the affected area in the magnetic field s region.

The controller 130 may control the type of the magnetic field generated from the magnetic field generator 110, and may control at least one of the strength, frequency, time, and pattern of the magnetic field as the type of the magnetic field.

In addition, the controller 130 may control the magnetic field generator 110 to generate the magnetic field stimulus corresponding to the magnetic field stimulation mode information input from the user. The magnetic field stimulation mode can be more easily understood through FIG.

Referring to FIG. 4, the nanoparticle concentrator 100 according to an embodiment of the present disclosure may receive magnetic field stimulation mode information from a user. For example, the N pulse stimulation mode, the S pulse stimulation mode, Any one of an alternating stimulation mode of an N pulse and an S pulse, an N pulse continuous stimulation mode, and an S pulse continuous stimulation mode may be input. Accordingly, the control unit 130 is a magnetic field stimulus corresponding to any one of the N pulse stimulation, S pulse stimulation, alternating stimulation of N pulses and S pulses, N pulse continuous stimulation and S pulse continuous stimulation from the magnetic field generating unit 110 The magnetic field generating unit 110 may be controlled to be generated.

In addition, the controller 130 may control at least one of the strength, frequency, time, and pattern of the magnetic field as the type of the magnetic field, thereby concentrating the nanoparticles to the affected part or conducting heat to the concentrated nanoparticles. This can be more readily understood with reference to FIG. 5.

Referring to FIG. 5, the controller 130 controls the type of the magnetic field of the magnetic field generating unit 110 ′ to concentrate the mode of the magnetic field generating unit 110 ′ and concentrate the nanoparticles on the affected area. It can be controlled in the exothermic mode to conduct heat to the nanoparticles.

Specifically, FIG. 5A illustrates the concentrated mode and FIG. 5B illustrates the heating mode.

In the concentrated mode as illustrated in FIG. 5A, the controller 130 may control the type of the magnetic field of the magnetic field generator 110 ′ at a frequency of 30 Hz or less in order to concentrate the nanoparticles.

In the heating mode as illustrated in FIG. 5B, the controller 130 may control the type of the magnetic field of the magnetic field generator 110 ′ at a high frequency frequency to conduct heat to the concentrated nanoparticles. 130 may be controlled to any one of 100 kHz to 300 kHz as a high frequency. At this time, as the magnetic field having a frequency of any one of 100 kHz to 300 kHz is generated from the magnetic field generating unit 110 ′, the magnetic body 120 ′ may be quickly magnetized or demagnetized to generate heat. Heat generated from the magnetic body 120 ′ ″ may be transferred to the nanoparticles 2 located in the magnetic field region s. Therefore, in the exothermic mode, heat generated from the exothermic magnetic material 120 ′ ″ may be transmitted to the nanoparticles 2, thereby necrosing the cancer cells in the cancer tissue or suppressing the proliferation of the cancer cells.

Meanwhile, the nanoparticle concentrator 100 according to an embodiment of the present disclosure may include a sensor unit (not shown) for measuring the number of nanoparticles concentrated on the affected part.

The sensor unit (not shown) may count the number of nanoparticles 2 concentrated in the magnetic field region s of the affected part. For example, the nanoparticles may be fluorescent materials, and the sensor unit may include a fluorescent sensor, an image sensor, an infrared sensor, and the like, which are capable of detecting nanoparticles, but are not limited thereto.

The controller 130 may control the type of the magnetic field of the magnetic field generator 110 in consideration of the measured value of the number of nanoparticles through the sensor unit.

In detail, the controller 130 may change the type of the magnetic field of the magnetic field generator 110 from the first type to the second type according to whether the number of nanoparticles concentrated on the affected area exceeds a predetermined criterion.

For example, the first type may be a type of concentrated mode in which the frequency of the magnetic field of the magnetic field generator 110 is 30 Hz or less, and the second type is a frequency in which the frequency of the magnetic field of the magnetic field generator 110 is between 100 kHz and 300 kHz. Phosphorus heating mode may be a type, but is not limited thereto.

The controller 130 controls the type of the magnetic field of the magnetic field generating unit 110 to a first type having a frequency of 30 Hz or less in order to concentrate the nanoparticles 2 in the affected area or the magnetic field area s, and the affected area or the magnetic field area. If it is determined that the number of nanoparticles concentrated in (s) exceeds a predetermined criterion, the controller 130 may change the type of the magnetic field from the first type to the second type, which is a frequency between 100 kHz and 300 kHz. At this time, the magnetic body 120 ', which is generated by the magnetic field having the frequency of the second type, may be changed into a heating magnetic body 120' '' that generates heat as it is magnetized or de-magnetically, and thus the heating magnetic body 120 '' 'may conduct heat to the nanoparticles concentrated within the affected or magnetic field region s.

In addition, the controller 130 controls the type of the magnetic field of the magnetic field generating unit 110 to be the first type during the first predetermined time for concentrating the nanoparticles, and during the second predetermined time after the first time has elapsed. The type of the magnetic field of the magnetic field generator 110 may be controlled as the second type. For example, the controller 130 may control the type of the magnetic field of the magnetic field generating unit 110 to be the first type for 10 minutes and to the second type for 3 minutes after 10 minutes have elapsed.

In addition, the controller 130 may change the frequency of the magnetic field generated from the magnetic field generator 110 at predetermined time intervals. In this case, the controller 130 may control the time interval in which the frequency is changed according to the type of the magnetic field. For example, when controlling the type of the magnetic field generated from the magnetic field generating unit 110 in the heating mode, the controller 130 may control the frequency to be changed every 10 seconds within a frequency between 100 kHz and 300 kHz. . Specifically, the controller 130 controls the frequency of the magnetic field to 100 kHz for 10 seconds, then to 230 kHz for 10 seconds, then to 150 kHz for 10 seconds, and then to 280 kHz for 10 seconds. The frequency can be controlled to change every 10 seconds. In this case, the frequency may be changed regularly or irregularly. In addition, as an example, when controlling the type of the magnetic field generated from the magnetic field generator 110 in the concentrated mode, the controller 130 may control the frequency to be changed every 30 seconds within a frequency of 30 Hz or less. In this case, the frequency may be changed regularly or irregularly as described above.

On the other hand, the nanoparticle concentrator 100 according to an embodiment of the present application may include a plurality of magnetic field generating unit 110, the position and number of the plurality of magnetic field generating unit 110 can be variously implemented. As an example, a configuration example of the plurality of magnetic field generators 110 may be more easily understood with reference to FIGS. 6 and 7.

Referring to FIG. 6, the nanoparticle concentrator 100 according to an exemplary embodiment of the present disclosure may include a first magnetic field generator 110 ′ A and a second magnetic field generator 110 ′ B as a plurality of magnetic field generators 110. ) And the third magnetic field generator 110 ′ C.

In this case, as an example, the first magnetic field generating unit 110 ′ A, the second magnetic field generating unit 110 ′ B, and the third magnetic field generating unit 110 ′ C each have a triangular angle so that the regions of the magnetic field generated by each of them cross each other. It can be arranged as. Specifically, the first magnetic field region s1 formed by the first magnetic body 120'A located in the first magnetic field generating unit 110'A and the second magnetic body located in the second magnetic field generating unit 110'B. The second magnetic field region s2 formed by the 120'B and the third magnetic field region s3 formed by the third magnetic body 120'C located in the third magnetic field generating unit 110'C mutually In order to intersect, the first magnetic field generator 110 ′ A to the third magnetic field generator 110 ′ C may be arranged at three angles. Through this arrangement, the nanoparticle concentrator 100 according to an embodiment of the present application concentrates the nanoparticles to the treatment site (or affected part) of the desired user as much as possible, and then conducts heat to the nanoparticles more effectively, thereby necrosing the cancer cells. You can.

In addition, when the plurality of magnetic field generators 110 are included, the controller 130 may control different types of magnetic fields generated from each of the plurality of magnetic field generators 110. For example, as shown in FIG. 6, the controller 130 controls the type of the magnetic field to be the first type of the first magnetic field generator 110 ′ A, and the second magnetic field generator 110 ′ B is the second type. Type control, and the third magnetic field generating unit 110 ′ C may be controlled by a third type different from the first type and the second type. Alternatively, the first magnetic field generating unit 110'A and the second magnetic field generating unit 110'B may be controlled by the first type, and the third magnetic field generating unit 110'C may be controlled by the second type. .

In addition, when the plurality of magnetic field generators 110 are included, the controller 130 may change not only the type of magnetic field but also the frequency change time, magnetic field stimulation time, and magnetic field strength of the magnetic field generated from each of the plurality of magnetic field generators 11. Can be controlled differently.

In FIG. 6, the shapes of the plurality of magnetic field generators 110'A, 110'B and 110'C and the plurality of magnetic bodies 120'A, 120'B and 120'C located in the respective embodiments are shown in FIG. Although only the shape of the magnetic field generating unit 110 'and the magnetic body 120' is illustrated, the shape of the magnetic field generating unit 110 '' and the magnetic body 120 '' according to the second embodiment is not limited thereto. May be applied.

Referring to FIG. 7, the nanoparticle concentrator 100 according to an exemplary embodiment of the present disclosure may include four magnetic field generators 110 ″ as a plurality of magnetic field generators 110. Can be placed.

In FIG. 7, for example, three magnetic bodies may be attached, inserted, or implanted as a plurality of spherical magnetic bodies 120 ″ to a user's body, and nanoparticles may be concentrated around the three spherical magnetic bodies 120 ″ as much as possible. Four magnetic field generating units 110 ″ may be positioned in up, down, left, and right, front and rear directions. As described above, the controller 1300 may differently control the type of magnetic field, the stimulus time, the stimulus frequency change time, and the like for each of the four magnetic field generators 110 ″.

Hereinafter, based on the details described above, the operation flow of the present application will be briefly described.

The method of driving the nanoparticle concentrator shown in FIG. 8 may be performed by the nanoparticle concentrator 100 described above. Therefore, even if omitted below, the content described with respect to the nanoparticle concentrator 100 may be equally applied to FIG. 8.

Referring to FIG. 8, in step S810, the magnetic field control signal may be generated through the controller 130.

In this case, in step S810, the controller 130 may generate a control signal for controlling the type of the magnetic field generated from the magnetic field generator 110 at a frequency of 30 Hz or less as the first type. Thereafter, the controller 130 may generate a control signal for controlling at a frequency of 30 Hz or less, and then generate a control signal for controlling the type of the magnetic field as a second type at a frequency between 100 kHz and 300 kHz.

Next, in step S820, a magnetic field may be generated through the magnetic field generator 110 based on the magnetic field control signal generated in step S810.

In this case, in operation S820, a magnetic field corresponding to a frequency of 30 Hz or less may be generated through the magnetic field generator 110 based on the first type of control signal. In operation S820, a magnetic field corresponding to a frequency between 100 kHz and 300 kHz may be generated through the magnetic field generator 110 based on the second type of control signal.

Next, in step S830, the magnetic body 120 may be magnetized by the magnetic field generated in step S820.

In this case, in step S830, the magnetic body 120 is magnetized by the magnetic field corresponding to the first type, so that the nanoparticles containing the drug may be concentrated in the magnetic field region s formed by the magnetic body 120.

In operation S830, the magnetic material 120 may be magnetized or demagnetized by a magnetic field corresponding to the second type, thereby generating heat from the magnetic material 120. Accordingly, heat generated from the magnetic body 120 may be conducted to the nanoparticles concentrated in the magnetic field region s, thereby more effectively inhibiting the proliferation of cancer cells and necrosis the cancer cells.

In addition, although not shown in the drawings, the method of driving the nanoparticle concentrator according to an embodiment of the present application may further include changing a type of the magnetic field generated from the magnetic field generator 110.

At this time, the type of the magnetic field may be changed based on the number of nanoparticles concentrated on the affected part. The type of magnetic field may also be controlled to operate with the type of preset magnetic field for a preset time. In addition, the type of the magnetic field may be controlled to change the frequency of the magnetic field at predetermined time intervals. More specific examples thereof have been described in more detail above, and thus will be omitted below.

In the above description, steps S810 to S830 may be further divided into additional steps or combined into fewer steps, according to an embodiment of the present disclosure. In addition, some steps may be omitted as necessary, and the order between the steps may be changed.

The method for driving a nanoparticle concentrator according to an embodiment of the present disclosure may be implemented in the form of program instructions that may be executed by various computer means and may be recorded in a computer readable medium. The computer readable medium may include program instructions, data files, data structures, etc. alone or in combination. Program instructions recorded on the media may be those specially designed and constructed for the purposes of the present invention, or they may be of the kind well-known and available to those having skill in the computer software arts. Examples of computer-readable recording media include magnetic media such as hard disks, floppy disks, and magnetic tape, optical media such as CD-ROMs, DVDs, and magnetic disks, such as floppy disks. Magneto-optical media, and hardware devices specifically configured to store and execute program instructions, such as ROM, RAM, flash memory, and the like. Examples of program instructions include not only machine code generated by a compiler, but also high-level language code that can be executed by a computer using an interpreter or the like. The hardware device described above may be configured to operate as one or more software modules to perform the operations of the present invention, and vice versa.

In addition, the method of driving the above-described nanoparticle concentrator may be implemented in the form of a computer program or an application executed by a computer stored in a recording medium.

The above description of the present application is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present application. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.

The scope of the present application is indicated by the following claims rather than the above description, and it should be construed that all changes or modifications derived from the meaning and scope of the claims and their equivalents are included in the scope of the present application.

Claims

At least one magnetic field generating unit generating a magnetic field;

At least one magnetic material magnetized by the magnetic field; And

A controller for generating a control signal for controlling an operation of the magnetic field generator;

Including,

Wherein the magnetic body is to concentrate the nanoparticles (nanoparticle) containing the drug introduced into the living body as magnetized by the magnetic field in the affected area in the region of the magnetic field, nanoparticle concentrator.
The method of claim 1,

The control unit,

And controlling at least one of the strength, frequency, time, and pattern of the magnetic field as a type of magnetic field generated from the magnetic field generator.
The method of claim 2,

The control unit,

Controlling the type of magnetic field to concentrate the nanoparticles or conduct heat to the nanoparticles.
The method of claim 3,

The controller controls the frequency of the magnetic field to any one of 100 kHz to 300 kHz,

The magnetic material is a nanoparticle concentrator, which is magnetized or demagnetized by a magnetic field having a frequency of any one of the 100 kHz to 300 kHz to generate heat to conduct heat to the nanoparticles.
The method of claim 2,

A sensor unit for measuring the number of nanoparticles concentrated on the affected part,

More,

The control unit,

And change the type of magnetic field from the first type to the second type depending on whether the number of nanoparticles concentrated on the affected area exceeds a predetermined criterion.
The method of claim 5,

The control unit,

The type of magnetic field is controlled at a frequency of 30 Hz or less as a first type to concentrate the nanoparticles,

If it is determined that the number of nanoparticles concentrated on the affected area exceeds a predetermined standard, the type of the magnetic field is controlled as a second type at a frequency between 100 kHz and 300 kHz,

The magnetic material is a nanoparticle concentrating device that is magnetized or demagnetized by a magnetic field having a frequency of the second type to generate heat to conduct heat to the nanoparticles.
The method of claim 2,

The control unit,

The type of the magnetic field is controlled at a frequency of 30 Hz or less as the first type for a first preset time for concentrating the nanoparticles,

Controlling the type of the magnetic field to a frequency between 100 kHz and 300 kHz as a second type for a preset second time after the first time has elapsed,

The magnetic material is a nanoparticle concentrating device that is magnetized or demagnetized by a magnetic field having a frequency of the second type to generate heat to conduct heat to the nanoparticles.
The method of claim 1,

The magnetic material,

And located in the affected area by at least one of attachment, insertion, and implantation within the magnetic field generator.
The method of claim 8,

Magnetic material located in the magnetic field generating unit,

Nanoparticle concentrator comprising a magnetic needle and a spherical magnetic material bound to the end of the magnetic needle.
The method of claim 9,

The magnetic field generating unit,

A magnetic field core having a through hole formed therein; And

A coil wound around the magnetic field core,

Including,

Wherein the magnetic material is located through the through-holes, nanoparticle concentrator.
The method of claim 8,

The magnetic material is a spherical magnetic material, nanoparticle concentrator.
The method of claim 2,

The control unit is to change the frequency of the magnetic field every predetermined time interval, nanoparticle concentrator.
The method of claim 2,

The control unit,

When a plurality of magnetic field generators are included, different types of magnetic fields generated from each of the plurality of magnetic field generators, the nanoparticle concentrator.
The method of claim 1,

The magnetic field generating unit,

Nanoparticle concentrator, which generates a pulsed electro-magnetic field (PEMF).
The method of claim 1,

The magnetic field generating unit includes a first magnetic field generating unit, a second magnetic field generating unit and a third magnetic field generating unit,

The first magnetic field generating unit, the second magnetic field generating unit and the third magnetic field generating unit is disposed at each triangular so that the regions of the magnetic field to generate each cross each other, nanoparticle concentrator.
In the driving method of the nanoparticle concentrator of any one of claims 1 to 15,

Generating a magnetic field control signal;

Generating a magnetic field based on the magnetic field control signal; And

Magnetizing the magnetic body by the magnetic field,

That includes, driving method of the nanoparticle concentrator.
The method of claim 16,

Generating the magnetic field control signal,

(a) generating a control signal for controlling the type of magnetic field as a first type at a frequency of 30 Hz or less; And

(b) generating a control signal after step (a) to control the type of magnetic field as a second type at a frequency between 100 kHz and 300 kHz,

Including,

The driving method of the nanoparticle concentrator,

Generating heat from the magnetic material magnetized by the second type of magnetic field,

That further comprises, the method of driving a nanoparticle concentrator.
A computer-readable recording medium having recorded thereon a program for executing the method of any one of claims 16 and 17 on a computer.